

Personal Information



Suebpong Tanasanvimon

Address: King Chulalongkorn Memorial Hospital

Country: Thailand

Curriculum Vitae

Research Interests

- Clinical and translational research in gastrointestinal oncology
- Clinical research in general oncology

Professional Experience & Appointments

Attending Medical Oncologist 2008-Present
King Chulalongkorn Memorial Hospital
Department of Medicine Bangkok, Thailand:

ASCO Long-term International Fellowship 2011-2012
University of Texas, MD Anderson Cancer Center
Department of Gastrointestinal Medical Oncology Texas, USA

Visiting Scientist 2010-2012
University of Texas, MD Anderson Cancer Center
Department of Gastroenterology Texas, USA

Clinical Fellow in Medical Oncology 2006-2008
King Chulalongkorn Memorial Hospital
Department of Medicine Bangkok, Thailand:

Resident in Internal Medicine 2003-2006
King Chulalongkorn Memorial Hospital
Department of Medicine Bangkok, Thailand:

Education

Masters of Science in Internal Medicine 2006-2008
Chulalongkorn University: Faculty of Medicine Bangkok, Thailand

Diploma: Thai Board of Medical Oncology 2006-2008
King Chulalongkorn Memorial Hospital
Department of Medicine Bangkok, Thailand:

Diploma: Thai Board of Internal Medicine 2003-2006
King Chulalongkorn Memorial Hospital
Department of Medicine Bangkok, Thailand:

Doctor of Medicine: First Class Honors
Chulalongkorn University: Faculty of Medicine

1994-2000
Bangkok, Thailand

Abstracts, Publications & Research

1. **Tanasanvimon S**, Issarasena Na Ayuthaya N, Phanthumchinda K. Clinical use of Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients. *J Med Assoc Thai* 2007;90:2277-83.
2. **Guha S, Tanasanvimon S, Sinnett-Smith J, Rozengurt E**. Role of protein kinase D signaling in pancreatic cancer *Biochem Pharmacol*. 2010;80(12):1946-54
3. Ochi N, Tanasanvimon S, Matsuo Y, Tong Z, Sung B, Aggarwal BB, Sinnett-Smith J, Rozengurt E, Guha S. [Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells.](#) *J Cell Physiol*. 2011;226(4):1074-81.
4. Vinayanuwattikun C, Sriuranpong V, **Tanasanvimon S**, Chantranuwat P, Mutirangura A. [Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.](#) *J Thorac Oncol*. 2011;6(11):1818-25.
5. Kittiwarawut A, Vorasettakarnkij Y, **Tanasanvimon S**, Manasnayakorn S, Sriuranpong V. [Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.](#) *Asia Pac J Clin Oncol*. 2013 Jun;9(2):155-61.
6. Kunkeaw N, Jeon SH, Lee K, Johnson BH, **Tanasanvimon S**, Javle M, Pairojkul C, Chamgramol Y, Wongfieng W, Gong B, Leelayuwat C, Lee YS. [Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma.](#) *Oncogene*. 2012 Aug 27. doi: 10.1038/onc.2012.382.
7. **Tanasanvimon S**, Chantranuwat P, Parinyanitikul N, Voravud N, Sriuranpong V. p53-associated differential response to platinum-gemcitabine and platinum-paclitaxel in advanced nonsmall cell lung cancer. *Asian Biomedicine Vol. 7 No. 2 April 2013*; 185-192
8. **Tanasanvimon S**, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. [High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study.](#) *Thromb Res*. 2014 Feb;133(2):154-7.
9. **Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisat W, Tanasanvimon S**. A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes. [Chemotherapy](#). 2017;62(2):134-139.
10. **Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ**. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. *J Gastrointest Oncol*. 2016 Dec;7(6):819-827.
11. **Pongmaneratanakul S, Tanasanvimon S, Pengsuparp T, Areepium N**. Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy. *Asian Pac J Cancer Prev*. 2017 Mar 1;18(3):857-861.

Awards and Honors

Long-term International Fellowship 2011 award from Conquer Cancer Foundation (former known as ASCO cancer foundation)

- To conduct research project
- "Micro RNA expression profile of Opisthorchis Viverri associated Cholangiocarcinoma (OV-CCA) and Non-OV associated CCA."
- Clinical observation in Gastrointestinal Medical Oncology at UT MD Anderson Cancer Center